

Biomarker-guided clinical trials for rare and very rare cancers

Horizon Europe

Gerado em: 8 de outubro de 2026

● PENDENTE

Código

HORIZON-MISS-2027-02-CANCER-03

Âmbito

Internacional

Localização

Europa

Curadoria

Marlene Faria

Detalhes Financeiros

Tipo de apoio

Fundo Perdido

Taxa Máxima de Financiamento

100%

Dotação

24M€

Valor Elegível do Projeto

7M€ - 9M€

Datas e Prazos

Data de Publicação

5 de outubro de 2026

Data de Abertura

10 de fevereiro de 2027

Fase única

16 de setembro de 2027 às 17:00 GMT+2

Descrição

Objectives

The main goal of this incentive is to advance biomarker-guided medicines and multi-modal treatment interventions specifically tailored for patients with rare and very rare cancers. The target group includes patients, researchers, physicians, innovators, startups, SMEs, charities, healthcare providers, and policymakers across EU Member States and Associated Countries. The aim is to enable access to early-stage trials, innovative technologies, and validated interventions that have the potential to significantly improve overall survival rates and expand therapeutic options where few exist today.

Funding

Funding is provided under a Horizon Europe Research and Innovation Action (RIA) within the framework of the EU Mission on Cancer. The topic has an indicative budget of €24 million, with the European Commission expecting to fund three projects. The expected EU contribution ranges between €7 million

and €9 million per project, although proposals requesting different amounts may be considered where adequately justified.

Despesas Elegíveis

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs
- Preclinical research
- Clinical trial costs
- Networking and meetings
- Stakeholder engagement
- Data management
- Regulatory consultation costs
- Open data infrastructure
- Patient and caregiver involvement activities

Bónus e Majorações

- Participation in EU Cancer Mission 'Diagnosis and treatment' cluster
- Collaboration with Knowledge Centre on Cancer resources

Elegibilidade

Setores Elegíveis

Saúde & Ciências da Vida

Modalidade de Candidatura

Consórcio / Copromoção

Tipologia das Empresas

- PME
- Grande
- Entidades privadas sem fins lucrativos
- Entidades públicas

Tipos de Ação

- Preclinical validation
- Clinical trials
- Innovative medicine validation
- Biomarker-guided drug development

- Patient engagement
- Open science data management
- Stakeholder coordination
- Research and Innovation Actions

Detalhes do Programa UE

ID da Chamada

HORIZON-MISS-2027-02-CANCER-03

Cluster

Mission

Destino

Cancer

Modo de Submissão

Single-stage

Contribuição UE

Around €7,000,000.00 to €9,000,000.00 per project

Projetos Esperados

3

Regra de Taxa de Financiamento

Up to 100% of eligible costs for Research and Innovation Actions (RIA)

Links Oficiais

Regulamento Oficial

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-03?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-MISS-2027-02-CANCER-03&isExactMatch=true&status=31094501,31094502,31094503>

Página no Grantavia

<https://grantavia.com/pt/incentives/biomarker-guided-clinical-trials-for-rare-and-very-rare-cancers>

Agendar reunião

<https://calendly.com/sandra-cardoso-epsa/reuniao>